Ebopiprant HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564467

CAS#: 2005486-32-6 (HCl)

Description: Ebopiprant, also known as OBE-022, is an Oral and Selective Prostaglandin F 2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. OBE022 exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects seen with indomethacin.

Chemical Structure

img
Ebopiprant HCl
CAS# 2005486-32-6 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 564467
Name: Ebopiprant HCl
CAS#: 2005486-32-6 (HCl)
Chemical Formula: C30H35ClFN3O5S2
Exact Mass: 599.19
Molecular Weight: 636.194
Elemental Analysis: C, 56.64; H, 5.55; Cl, 5.57; F, 2.99; N, 6.61; O, 12.57; S, 10.08

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 2005486-31-5 (free base)   2005486-32-6 (HCl)   2005486-34-8 (fumarate)   2005486-33-7 (sulfate)   2005486-42-8 (tosylate)   2005486-37-1 (citrate)   2005486-38-2 (esylate)    

Synonym: OBE-022; OBE 022; OBE022; Ebopiprant HCl; Ebopiprant hydrochloride

IUPAC/Chemical Name: (S)-3-((S)-3-([1,1'-Biphenyl]-4-ylsulfonyl)thiazolidine-2-carboxamido)-3-(4-fluorophenyl)propyl L-valinate hydrochloride

InChi Key: BKHLLRSGQHTVMA-LKJZLNBCSA-N

InChi Code: InChI=1S/C30H34FN3O5S2.ClH/c1-20(2)27(32)30(36)39-18-16-26(23-8-12-24(31)13-9-23)33-28(35)29-34(17-19-40-29)41(37,38)25-14-10-22(11-15-25)21-6-4-3-5-7-21;/h3-15,20,26-27,29H,16-19,32H2,1-2H3,(H,33,35);1H/t26-,27-,29+;/m0./s1

SMILES Code: N[C@@H](C(C)C)C(OCC[C@H](NC([C@@H]1N(CCS1)S(C(C=C2)=CC=C2C3=CC=CC=C3)(=O)=O)=O)C4=CC=C(F)C=C4)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info: Preterm birth is the major challenge in obstetrics, affecting ∼10% of pregnancies. Pan-prostaglandin synthesis inhibitors [nonsteroidal anti-inflammatory drugs (NSAIDs)] prevent preterm labor and prolong pregnancy but raise concerns about fetal renal and cardiovascular safety.

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 636.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Coates S, Pohl O, Gotteland JP, Täubel J, Lorch U. Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Ther Innov Regul Sci. 2020 Jan;54(1):184-194. doi: 10.1007/s43441-019-00044-y. Epub 2020 Jan 6. PMID: 32008245.


2: Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. Br J Clin Pharmacol. 2019 Jul;85(7):1516-1527. doi: 10.1111/bcp.13925. Epub 2019 May 11. PMID: 30891820; PMCID: PMC6595366.


3: Pohl O, Chollet A, Kim SH, Riaposova L, Spézia F, Gervais F, Guillaume P, Lluel P, Méen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP. OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. J Pharmacol Exp Ther. 2018 Aug;366(2):349-364. doi: 10.1124/jpet.118.247668. Epub 2018 May 18. PMID: 29777040.


4: Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. Br J Clin Pharmacol. 2018 Aug;84(8):1839-1855. doi: 10.1111/bcp.13622. Epub 2018 Jun 5. PMID: 29708281; PMCID: PMC6046484.


5: Täubel J, Lorch U, Coates S, Fernandes S, Foley P, Ferber G, Gotteland JP, Pohl O. Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clin Pharmacol Drug Dev. 2018 Nov;7(8):889-900. doi: 10.1002/cpdd.447. Epub 2018 Feb 28. PMID: 29489066; PMCID: PMC6221050.